Clinical trial
Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of…
NCT00056550 · rEVO Biologics, Industry · Completed
Key facts
| NCT number | NCT00056550 |
|---|---|
| Title | Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. |
| Official title | A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations. |
| Acronym | rhAT |
| Lead sponsor | rEVO Biologics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Antithrombin Deficiency, Congenital |
| Intervention type | Biological |
| Interventions | Recombinant Human Antithrombin (rhAT) |
| Enrollment | 14 |
| Start date | Dec 1, 2002 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Mar 18, 2003 |
| Last update posted | Oct 16, 2012 |
| Countries | France, Germany, Italy, Sweden, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: